NCDEU is a scientific meeting that focuses on the latest developments in psychopharmacologic clinical research and related methodology. The meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees. In addition to the topics noted below, the NCDEU program includes presentations and information from the American Society of Clinical Psychopharmacology (ASCP) and its federal partners, the National Institute of Mental Health (NIMH), and the Food and Drug Administration (FDA).

NCDEU focuses on timely issues in psychiatric clinical research including:

	Clinical trials design, methodology, diagnosis, clinical assessment,   patient ascertainment, and recruitment
	Measures of functional outcome for psychosocial and biomedical   intervention research across a range of disorders and diverse populations
	Pharmacogenetics, biomarkers, and other means towards personalizing   interventions
	Disparities in the availability of clinical treatments and how cultural and   social factors influence intervention delivery
	New technologies that can advance the development of new interventions
	Novel statistical approaches to the analysis and interpretation of clinical   trial data
	The translation of research into practice
	The impact of public policy and health care regulation on treatment   decision-making and clinical response

The program emphasizes the presentation of information that has not been
previously published or presented.